Asymptomatic hyperuricaemia: to treat or not to treat?

Lazaros I. Sakkas, MD, DM, PhD, FRCP Emeritus Professor of Medicine and Rheumatology, University of Thessaly, Larissa

Asymptomatic hyperurecaemia(aHU)the size of the problem

• 10-20% of adult individuals

Mikuls TR Ann Rheum Dis 2005;64:267 Zhu Y Arthritis Rheum 2011;63:3136 Kapenanovic MC Arthritis Res Ther 2018;20:190 Arthritis Research & Therapy

RESEARCH ARTICLE

Open Access

(E) CrossMark

The risk of clinically diagnosed gout by serum urate levels: results from 30 years follow-up of the Malmö Preventive Project cohort in southern Sweden

Meliha C. Kapetanovic^{1*}, Peter Nilsson^{2,3}, Carl Turesson⁴, Martin Englund⁵, Nicola Dalbeth⁶ and Lennart Jacobsson⁷

33,335 participants, Follow up (mean): 28.2 years At baseline HU was correlated with BMI, lower eGFR, Hypertension, DM, CVD, kidney stones, ESR, alcohol(men) J Clin Hypertens (Greenwich), 2016 Jan;18(1):53-9. doi: 10.1111/jch.12627. Epub 2015 Jul 25.

Association Between Serum Uric Acid Levels/Hyperuricemia and Hypertension Among 85,286 Japanese Workers.

Yokokawa H¹, Fukuda H¹, Suzuki A¹, Fujibayashi K¹, Naito T¹, Uehara Y¹, Nakayama A², Matsuo H², Sanada H^{3,4}, Jose PA⁵, Miwa Y⁶, Hisaoka T¹, Isonuma H¹.

Arthritis Rheum. 2009 July 15; 61(7): 885-892. doi:10.1002/art.24612.

Hyperuricemia and Risk of Stroke: A Systematic Review and Meta-analysis

Seo Young Kim, MD^{1,2}, James P Guevara, MD, MPH^{2,3}, Kyoung Mi Kim, MD⁴, Hyon K Choi, MD, DrPH⁵, Daniel F. Heitjan, PhD^{2,6}, and Daniel A Albert, MD⁷

Elevated SUA is an independent risk factor for stroke (RR:1.47[1.19-1.76]) and stroke mortality (RR:1.26[1.12-1.39])

Eur J Clin Nutr. 2019 Feb 20. doi: 10.1038/s41430-019-0405-1. [Epub ahead of print]

Asymptomatic hyperuricemia and incident stroke in elderly Chinese patients without comorbidities.

Tu W¹, Wu J², Jian G², Lori J³, Tang Y⁴, Cheng H⁴, Wu X⁵, Wang N⁶.

Asymptomatic hyperuricemia carried a significant risk of stroke events

ORIGINAL ARTICLE



Serum Uric Acid Is Independently Associated with Coronary Calcification in an Asymptomatic Population

Loretta Zsuzsa Kiss¹ : Zsolt Bagyura¹ · Csaba Csobay-Novák¹ · Árpád Lux¹ · Lívia Polgár¹ · Ádám Jermendy¹ · Pál Soós¹ · Zsolt Szelid¹ · Pál Maurovich-Horvat^{1,2} · Dávid Becker¹ · Béla Merkely¹

Arthritis Care Res (Hoboken). 2010 February ; 62(2): 170-180. doi:10.1002/acr.20065.

Hyperuricemia and Coronary Heart Disease: A Systematic Review and Meta-Analysis

Seo Young Kim, MD, MSCE^{1,2}, James P. Guevara, MD, MPH^{3,4}, Kyoung Mi Kim, MD⁵, Hyon K. Choi, MD, DrPH⁶, Daniel F. Heitjan, PhD^{3,7}, and Daniel A. Albert, MD⁸

Elevated SUA increased CHD mortality in women(RR:1.67[1.30-2.04])



European Journal of Heart Failure (2014) 16, 15–24 doi:10.1093/eurjhf/hft132


Uric acid and risk of heart failure: a systematic review and meta-analysis

He Huang¹, Baotao Huang¹, Yulin Li³, Yan Huang², Jing Li^{2*}, Hongmei Yao¹, Xianchao Jing¹, Jianrong Chen², and Ji Wang²

Elevated SUA is an independent risk factor for CVD and heart failure

Elevated sUA: cause or biomarker of disease?

During UA generation reactive oxygen species are produced



Proc. Natl. Acad. Sci. USA Vol. 78, No. 11, pp. 6858-6862, November 1981 Biochemistry

Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: A hypothesis

(lipid peroxidation/ascorbic acid/primate evolution/erythrocyte aging)

BRUCE N. AMES*, RICHARD CATHCART*, ELIZABETH SCHWIERS*, AND PAUL HOCHSTEIN†

Table 2. Effect of urate and ascorbate on t-butylhydroperoxideinduced hemolysis of human erythrocytes

Additions	% hemolysis		
	4 hr	7 hr	20 hr
None	0	0	3 ± 1
t-Butylhydroperoxide at 200 μ M	5 ± 1	14 ± 1	100 ± 2
+ Urate at 10 µM	0	4 ± 1	17 ± 2
$50 \mu M$	0	0	5 ± 1
100 µM	0	0	6 ± 1
+ Ascorbate at 10 μ M	0	2 ± 1	9 ± 2
50 µM	0	0	5 ± 1
100 µM	0	0	4 ± 1

Serum UA is a strong antioxidant

Uric acid-iron ion complexes

A new aspect of the antioxidant functions of uric acid

Kelvin J. A. DAVIES,*†§ Alex SEVANIAN,*‡ Samar F. MUAKKASSAH-KELLY* and Paul HOCHSTEIN*† *Institute for Toxicology, †Department of Biochemistry and ‡Department of Pathology, University of Southern California, 1985 Zonal Avenue, HSC-PSC 614-616, Los Angeles, CA 90033, U.S.A.






Fig. 2. Inhibition of ascorbate oxidation by urate

Initial rates of oxidation of $100 \,\mu$ M-ascorbate (\bigcirc) measured by decrease in A_{285} in the presence of $10 \,\mu$ M-FeCl₃±urate, and percentages of initial urate concentrations (5.0 μ M-1.0 mM) remaining (\bigcirc) after 1 min incubations with 100 μ M-ascorbate + 10 μ M-FeCl₃. Experi-

Uric Acid Contributes Greatly to Hepatic Antioxidant Capacity **Besides Protein**

T. MIKAMI¹, M. SORIMACHI²






Protein-free hepatic cytosol Allopurinol-treated mice Uricase in protein-free hepatic cytosol of control mice

Total-radical trapping antioxidant parameter(TRAP)

UA is a strong antioxidant in tissues




Oxygen free radicals >> antioxidants: oxidative stress



OPEN


Relationship between oxidative stress and inflammation in hyperuricemia

Analysis based on asymptomatic young patients with primary hyperuricemia 45.00-




MDA:malondialdehyde SOD: superoxide dismutase


Only a small percentage of HU pts will develop gout after 15 years



Asymptomatic HU: Urate deposition



Dalbeth N, Ann Rheum Dis 2015;74:908



Normal hyaline cartilage

MSU deposition on superficial surface of cartilage

CPPD within cartilage

Grassi W, Sem AR 2006;36:197

Dual energy CT in 45 patients with asymptomatic HU sUA:6.5-14.4 mg/dL MSU deposits:15%

 Table 1
 Association between patient characteristics and presence or absence of MSU crystal deposits on DECT scans among patients with asymptomatic hyperuricemia (n=46)

	Univariable OR	
Mean±SD or %	(95% CI)	sUA-adjusted OR (95% CI)
7.8±1.0	1.36 (0.63 to 2.95)	-
62±8	1.20 (1.03 to 1.39)	1.21 (1.03 to 1.41)
41%	1.08 (0.21 to 5.49)	1.06 (0.21 to 5.47)
36.4±6.3	0.97 (0.85 to 1.11)	0.94 (0.81 to 1.10)
54%	0.97 (0.19 to 4.93)	0.87 (0.16 to 4.62)
1.04±0.3	0.92 (0.08 to 11.19)	0.62 (0.05 to 8.53)
8.7±14.7	1.00 (0.94 to 1.06)	1.00 (0.94 to 1.06)
	7.8±1.0 62±8 41% 36.4±6.3 54% 1.04±0.3	Mean±SD or % (95% Cl) 7.8±1.0 1.36 (0.63 to 2.95) 62±8 1.20 (1.03 to 1.39) 41% 1.08 (0.21 to 5.49) 36.4±6.3 0.97 (0.85 to 1.11) 54% 0.97 (0.19 to 4.93) 1.04±0.3 0.92 (0.08 to 11.19)

DECT, dual-energy CT; hs-CRP, high-sensitivity C reactive protein; MSU, monosodium urate; sUA, serum uric acid.

Wang P RMD Open 2018;4:e000593

Arthritis Rheumatol. 2018 Nov;70(11):1847-1852. doi: 10.1002/art.40572. Epub 2018 Aug 27.

Brief Report: Monosodium Urate Monohydrate Crystal Deposits Are Common in Asymptomatic Sons of Patients With Gout: The Sons of Gout Study.

Abhishek A¹, Courtney P², Jenkins W¹, Sandoval-Plata G¹, Jones AC², Zhang W¹, Doherty M¹.


131 sons(sUA ≥6 mg/dL in 64.1%) 1st MTP MSU deposits: 29.8%

No MSU deposits in pts with sUA <5 mg/dL

MSU deposits correlated with joint effusion: -RRadj:9.4 (95%CI 3.6-24.6)

Silent Monosodium Urate Crystal Deposits Are Associated With Severe Coronary Calcification in Asymptomatic Hyperuricemia: An Exploratory Study.

Andrés M¹, Quintanilla MA², Sivera F², Sánchez-Payá J³, Pascual E⁴, Vela P⁴, Ruiz-Nodar JM³.



Page 1 of 24

RESEARCH




Serum uric acid levels and multiple health outcomes: umbrella review of evidence from observational studies, randomised controlled trials, and Mendelian randomisation studies

OPEN ACCESS

Xue Li *PhD student*¹, Xiangrui Meng *PhD student*¹, Maria Timofeeva *statistical geneticist*², Ioanna Tzoulaki *senior lecturer*³, Konstantinos K Tsilidis *assistant professor*^{3 4}, John PA Ioannidis *professor*⁵, Harry Campbell *professor*¹, Evropi Theodoratou *chancellor's fellow*^{1 2}

Conclusion Despite a few hundred systematic reviews, metaanalyses, and Mendelian randomisation studies exploring 136 unique health outcomes, convincing evidence of a clear role of SUA level only exists for gout and nephrolithiasis.




MRI: no crystals

Arthroscopy:crystals


Biopsy:granulomatous inflammation

In a patient with 1st attack of gout



Patient with tophaceous gout 2-dimensonalm DECT: crystals within an erosion

Perez-Ruiz F Adv Ther 2015';32:31



Perez-Ruiz Adv Ther 2015;32:31


Does ULT improve outcome?

J Investig Med. 2015 Dec;63(8):924-9. doi: 10.1097/JIM.00000000000242.

Lowering Uric Acid With Allopurinol Improves Insulin Resistance and Systemic Inflammation in Asymptomatic Hyperuricemia.

Takir M¹, Kostek O, Ozkok A, Elcioglu OC, Bakan A, Erek A, Mutlu HH, Telci O, Semerci A, Odabas AR, Afsar B, Smits G, ALanaspa M, Sharma S, Johnson RJ, Kanbay M.

Allopurinol might decrease the risk of myocardial infarction



Dalbeth N, Ann Rheum Dis 2015;74:908

Cochrane Database Syst Rev. 2017 Apr 13;4:CD008652. doi: 10.1002/14651858.CD008652.pub3.

Pharmacotherapy for hyperuricemia in hypertensive patients. <u>Gois PHE¹, Souza ERM²</u>.

AUTHORS' CONCLUSIONS: the RCT data available at present are insufficient to know whether UA-lowering therapy also lowers BP. More studies are needed.

Cardiovascular effects of urate-lowering therapies in patients with chronic gout: a systematic review and meta-analysis.

Zhang T¹, Pope JE¹.

CONCLUSION: RCT data do not suggest differences in CV events among ULTs in gout.

Trials had few events despite high-risk patients being enrolled and may have been too short to show CV reduction by controlling inflammatory attacks and lowering UA.



Contents lists available at ScienceDirect Journal of Advanced Research



Review

Asymptomatic hyperuricemia and chronic kidney disease: Narrative review of a treatment controversial



No benefit

Theodoros Eleftheriadis, Spyridon Golphinopoulos, Georgios Pissas, Ioannis Stefanidis*

Department of Nephrology, University of Thessaly, School of Medicine, Mezourlo Hill, 41110 Larissa, Greece

there may be an improvement of renal function with allopurinol. However, -Limited No of patients. -Insufficient information on AEs and on incidence of ESRD

Am J Kidney Dis. 2018 Dec;72(6):798-810. doi: 10.1053/j.ajkd.2018.06.028. Epub 2018 Sep 1.

Febuxostat Therapy for Patients With Stage 3 CKD and Asymptomatic Hyperuricemia: A Randomized Trial.

Kimura K¹, Hosoya T², Uchida S³, Inaba M⁴, Makino H⁵, Maruyama S⁶, Ito S⁷, Yamamoto T⁸, Tomino Y⁹, Ohno I¹⁰, Shibagaki Y¹¹, Iimuro S¹², Imai N¹³, Kuwabara M¹⁴, Hayakawa H¹⁵, Ohtsu H¹⁶, Ohashi Y¹⁷; FEATHER Study Investigators.

ULT:benefit vs harm

Withdrawal due to adverse effects(follow up 24-52 weeks)

- Allopurinol (100-300 mg/d): 77/1,000
- Febuxostat (80 mg/d): 68/1,000

Seth R, Cochrane Database Syst Rev 2014

aHU-management

- Identify cause of hyperurecemia and manage
 - Alcohol drinking
 - Drugs
- Identify comorbidities and manage
 - Hypertension
 - CV risk score
 - BMI
 - Abdominal circumference
- U/S for MSU deposits in joints, kidneys, tendons
- Monitor sUA and renal function

Stamp L, Semin AR 2017